Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 8/20 | 0.48 |
| ▸ | PRTN3 | P24158 | 2/20 | 0.46 |
| ▸ | ELANE | P08246 | 2/20 | 0.45 |
| ▸ | KLK1 | P06870 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19441127 | 0.91 | BTN3A1 (0.58) | BTN3A1PRTN3ELANEKLK1LMNA | |
| SCHEMBL19441122 | 0.91 | BTN3A1 (0.58) | BTN3A1PRTN3ELANEKLK1LMNA | |
| SCHEMBL19189391 | 0.91 | BTN3A1 (0.58) | BTN3A1PRTN3ELANEKLK1LMNA | |
| SCHEMBL19441135 | 0.91 | BTN3A1 (0.58) | BTN3A1PRTN3ELANEKLK1LMNA | |
| SCHEMBL19189604 | 0.91 | BTN3A1 (0.58) | BTN3A1PRTN3ELANEKLK1LMNA | |
| SCHEMBL16587346 | 0.88 | BTN3A1 (0.49) | BTN3A1PRTN3LMNA | |
| SCHEMBL16587345 | 0.88 | BTN3A1 (0.49) | BTN3A1PRTN3LMNA | |
| SCHEMBL16587348 | 0.88 | BTN3A1 (0.49) | BTN3A1PRTN3LMNA | |
| SCHEMBL30897058 | 0.86 | BTN3A1 (0.58) | BTN3A1PRTN3ELANEKLK1 | |
| SCHEMBL16587342 | 0.85 | BTN3A1 (0.57) | BTN3A1PRTN3ELANELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10196419-B2 | Processes and intermediates for preparing anti-HIV agents | GILEAD SCIENCES, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20180079773-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING ANTI-HIV AGENTS | GILEAD SCIENCES, INC. | 2018-03-22 | — | — | US | disclosed |
| US-9783567-B2 | Processes and intermediates for preparing anti-HIV agents | GILEAD SCIENCES, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| EP-3199537-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING ANTI-HIV AGENTS | GILEAD SCIENCES, INC. (US) | 2017-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196419-B2 | Processes and intermediates for preparing anti-HIV agents | SAMHD1, DHPS, LSS | BTN3A1 4464/4885PRTN3 1576/4885ELANE 2143/4885 |
| US-20180079773-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING ANTI-HIV AGENTS | SAMHD1, DHPS, LSS | BTN3A1 4464/4885PRTN3 1576/4885ELANE 2143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.